Bortezomib (Velcade®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001451
English
Authors' recommendations:
Bortezomib (Velcade®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Bortezomib (Velcade®) should be restricted for use in combination with dexamethasone. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised. Bortezomib (Velcade®) is not recommended for use within NHS Wales in combination with pegylated liposomal doxorubicin.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1807
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Multiple Myeloma
- Adult
- Boronic Acids
- Pyrazines
- Antineoplastic Agents
- Bortezomib
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.